Skip to Content
Søk Menu
3.-7. JUNI 2022

Følg med når vi dekker ASCO 2022 | American Society of Clinical Oncology

Stay tuned

News from ASCO 2023

Oluf Dimitri Røe

Can we predict bladder cancer using the HUNT model?

/ Oluf Dimitri Røe
BlærekreftASCO23 Play the Video
Stine Bakkensen Bruun

Circulating methylated-HOXA9 tumor DNA as a biomarker in recurrent breast cancer

/ Stine Bakkensen Bruun
BrystkreftASCO23 Play the Video
Lars Henrik Jensen

Neoadjuvant chemotherapy for locally advanced colon cancer does not change OS

/ Lars Henrik Jensen
TarmkreftASCO23 Play the Video

Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma

/ BestPractice Nordic
MelanomASCO23

Adjuvant Osimertinib – New Standard of Care for Patients with Resected EGFR-mutated NSCLC

/ BestPractice Nordic
LungekreftASCO23

Adjuvant pembrolizumab continue to demonstrate significant improvements for patients with stage IIB/IIC melanoma

/ BestPractice Nordic
MelanomASCO23

Prolonged Progression-Free Survival in Patients with Advanced Ovarian Cancer

/ BestPractice Nordic
Gynekologisk kreftASCO23

Pan tumor study – Effectively Treatment for HER2-Expressing Cancers Regardless of Tumor Location

/ BestPractice Nordic
KreftASCO23HER2
Martin Hutchings

Promising Findings for R/R Large B-cell Lymphoma – Glofitama and Epcoritamab Show Curative Potential

/ Martin Hutchings
LymfomASCO23EHA23 Play the Video
Sagar Lonial

Exciting News for CAR T Cell Therapy to Heavily Treated Patients with Multiple Myeloma

/ Sagar Lonial
ASCO23EHA23CAR-TMyelomatose Play the Video

Kommende events

Følg med her når vi dekker de viktigste høydepunkter fra kongresser. Vi publiserer i form av abstracts, artikler og MEDtalks med internasjonale og nasjonale sentrale meningsledere.

Se mer her

News from ASCO 2023

Jeanne Tie

The randomized DYNAMIC Trial: ctDNA-guided approach towards adjuvant chemotherapy

/ Jeanne Tie
Kolorektal kreftASCO22 Play the Video
David Cella, Dr

HRQoL as Prognostic Value for Overall Survival in Patients with RCC Receiving ICIs

/ David Cella
NyrekreftASCO22 Play the Video

Novel Agent Increases PFS for Patients with endocrine-resistant HR+/HER2- metastatic breast cancer

/ BestPractice Nordic
BrystkreftASCO22

Ibrutinib added to Standard-of-Care Therapy improves PFS by 50% for Older Patients with Newly Diagnosed Mantle Cell Lymphoma

/ BestPractice Nordic
LymfomASCO22

Health-related quality of life is associated with clinical outcomes in patients with advanced renal cell carcinoma

/ BestPractice Nordic
NyrekreftASCO22

Nivolumab in combination with relatlimab significantly improved PFS in patients with previously untreated metastatic or unresectable melanoma

/ BestPractice Nordic
ASCO22Hudcancer

ASCO-høydepunkter fra 2021

Relatlimab + nivolumab: a potential new combination in first-line advanced melanoma

/ Marco Donia
MelanomASCO21 Play the Video

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

/ Onkologi / Ghassan Abou-Alfa

First-line treatment with relatinib + nivolumab demonstrated significant PFS benefit in patients with advanced melanoma.

/ Onkologi / Evan J. Lipson

Significantly improved pathological complete response with nivolumab + chemotherapy in NSCLC

/ Onkologi / Jonathan Spicer

Neoadjuvant nivolumab + chemotherapy improved pathological complete response rate regardless the stage of NSCLC

/ Onkologi / BestPractice Nordic

Positive results presented by the VISION trial

/ Onkologi / BestPractice Nordic

Results of OlympiA are practice changing in treatment of breast cancer

  • / BestPractice Nordic

Abstracts og MEDtalks fra ASCO 2020

The SPARTAN study – the treatment of non-metastatic castration-resistant prostate cancer

/ Eric J. Small
KreftProstatakreftASCO20

CheckMate 9LA – Investigating the role of immunotherapy combinations in patients with non-small cell lung cancer

/ Martin Reck
ImmunterapiLungekreftKjemoterapiASCO20

ASCO20: Key takeways from ASCO20 Virtual in prostate cancer

/ Eric J. Small
ProstatakreftASCO20 Play the Video

ASCO20: Patients with non metastatic castration resistant prostate cancer

/ Eric J. Small
ProstatakreftASCO20 Play the Video

ASCO20: Significant improvement in survival for patients with stage IV/recurrent NSCLC

/ Martin Reck
ASCO20NSCLC Play the Video

ASCO20: Can you describe what characterizes the group of patients with non-metastatic castration-resistant prostate cancer?

/ Eric J. Small
ProstatakreftASCO20 Play the Video
Mere

Vi dekket også ASCO 2019

ASCO 2019: Flere interessante opfølgende studier af lungecancer

/ Odd Terje Brustugun
LungekreftASCO19 Play the Video

ASCO 2019: The first gene expression analysis of patients with advanced breast cancer treated with ribociclib-containing therapy

/ Yen-Shen Lu
BrystkreftASCO19 Play the Video

ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

/ Peter Schmid
BrystkreftASCO19 Play the Video

ASCO 2019: First-line treatment of patients with HER2-positive metastatic breast cancer – 4 years of long-term follow-up data

/ Sandra Swain
BrystkreftASCO19 Play the Video

ASCO 2019: Affordable Care Act ensures early diagnosis and treatment of ovarian cancer

/ Anna Jo Smith
ASCO19Gynekologisk kreft Play the Video

ASCO 2019: Private Insurance and higher regional Incomes predict longer survival for Multiple Myeloma

/ Kamal Chamoun
MyelomatoseASCO19 Play the Video

ASCO 2019: Gratifying new treatment of advanced Urothelial Cancer

/ Daniel Peter Petrylak
BlærekreftASCO19 Play the Video

ASCO 2019: Paradigm shift in treatment of metastatic cutaneous squamous cell carcinoma

/ Michael R. Migden
HudkreftASCO19 Play the Video
Load more

Back to top